AU2001282857A1 - Peptide and polypeptide inhibitors of complement c1s - Google Patents

Peptide and polypeptide inhibitors of complement c1s

Info

Publication number
AU2001282857A1
AU2001282857A1 AU2001282857A AU8285701A AU2001282857A1 AU 2001282857 A1 AU2001282857 A1 AU 2001282857A1 AU 2001282857 A AU2001282857 A AU 2001282857A AU 8285701 A AU8285701 A AU 8285701A AU 2001282857 A1 AU2001282857 A1 AU 2001282857A1
Authority
AU
Australia
Prior art keywords
complement
peptide
polypeptide inhibitors
polypeptide
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001282857A
Inventor
Brian A. Fox
Paul O Sheppard
Robert R. West
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of AU2001282857A1 publication Critical patent/AU2001282857A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001282857A 2000-06-21 2001-06-18 Peptide and polypeptide inhibitors of complement c1s Abandoned AU2001282857A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21299800P 2000-06-21 2000-06-21
US60/212,998 2000-06-21
PCT/US2001/019405 WO2001098365A2 (en) 2000-06-21 2001-06-18 Peptide and polypeptide inhibitors of complement c1s

Publications (1)

Publication Number Publication Date
AU2001282857A1 true AU2001282857A1 (en) 2002-01-02

Family

ID=22793322

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001282857A Abandoned AU2001282857A1 (en) 2000-06-21 2001-06-18 Peptide and polypeptide inhibitors of complement c1s

Country Status (5)

Country Link
US (2) US7071299B2 (en)
EP (1) EP1349874A2 (en)
AU (1) AU2001282857A1 (en)
CA (1) CA2413830A1 (en)
WO (1) WO2001098365A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
JP2005504025A (en) * 2001-07-20 2005-02-10 アイトゲネシシェ テクニシェ ホッヒシュル チューリッヒ（エーテーハーツェット） Use and composition of biological agents derived from sulfonated or sulfated amino acids
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
AU2003270330B2 (en) * 2002-09-06 2009-07-30 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component C5
US7482376B2 (en) * 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
US7385066B2 (en) 2005-03-16 2008-06-10 Janssen Pharmaceutica N.V. Thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditions
JP6134268B2 (en) * 2010-12-06 2017-05-24 ザ ユニバーシティ オブ ブリティッシュ コロンビア Granzyme B inhibitor compositions, methods and uses for promoting wound healing
JP6538561B2 (en) 2012-10-25 2019-07-03 バイオベラティブ・ユーエスエイ・インコーポレイテッド Anti-complement C1s antibodies and their uses
AU2013337638B2 (en) 2012-11-02 2018-10-25 Bioverativ Usa Inc. Anti-complement C1s antibodies and uses thereof
EP3193906B1 (en) * 2014-09-18 2020-11-11 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of Holy and Undiv. Trinity of Queen Elizabeth near Dublin Use of peptide inhibitors of il-36 proteolytic processing for the treatment and/or reduction of inflammation
ES2938359T3 (en) 2015-04-06 2023-04-10 Bioverativ Usa Inc Humanized anti-C1s antibodies and methods of using them

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9800817D0 (en) * 1998-01-16 1998-03-11 Bio Discovery Ltd Serine protease inhibitors

Also Published As

Publication number Publication date
US20020102256A1 (en) 2002-08-01
WO2001098365A2 (en) 2001-12-27
EP1349874A2 (en) 2003-10-08
US7071299B2 (en) 2006-07-04
US20050267035A1 (en) 2005-12-01
WO2001098365A3 (en) 2003-07-03
CA2413830A1 (en) 2001-12-27

Similar Documents

Publication Publication Date Title
AU3972697A (en) Inhibitors of cysteine protease
IL153970A0 (en) Promyostatin peptides and methods of using same
AU7473398A (en) Inhibitors of protein isoprenyl transferases
AU2484399A (en) Controlled release delivery of peptide or protein
AU4236796A (en) Cysteine protease and serine protease inhibitors
AU2002254328A1 (en) Inhibitors and disassemblers of fibrillogenesis
EP0923535A4 (en) Inhibitors of cysteine protease
AU2001282857A1 (en) Peptide and polypeptide inhibitors of complement c1s
AU7179598A (en) Benzothiazo and related heterocyclic group-containing cysteine and serine protease inhibitors
AU2002227279A1 (en) Polynucleotide and polypeptide sequences of putative transporters and ion channells
AU6536200A (en) Proteases and protease inhibitors
AU1287100A (en) Peptide inhibitor of browman-birk type
HK1039276A1 (en) Hydroxamate-containing cysteine and serine protease inhibitors
AU4229599A (en) Protease inhibitor peptides
GB2351494B (en) Interactions of Ku peptides and applications thereof
AU2587499A (en) Suppression of alpha-amylase and protease expression using serine/threonine protein kinase
AU6975001A (en) Metalloprotease peptide substrates and methods
AU6977096A (en) Ketomethylene group-containing cysteine and serine protease inhibitors
AUPP182398A0 (en) Cyclic peptide inhibitors of pla2
AU6109698A (en) Analgesic peptides from venom of (grammostola spatulata) and use thereof
AU2001277750A1 (en) Use of polypeptide
AU4169997A (en) Thiomethylene group-containing aldehyde cysteine and serine protease inhibitors
AU2002335119A1 (en) Antiretroviral compositions comprising thymosin alpha peptides and protease inhibitors
AU2001233333A1 (en) Par4 peptides and polypeptides
AU3703200A (en) Recombinant protein c activator and uses therefor